Exagen (NASDAQ:XGN – Get Free Report) and Allurion Technologies (NYSE:ALUR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Insider & Institutional Ownership
75.3% of Exagen shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 8.1% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Exagen and Allurion Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exagen | $66.57 million | 1.81 | -$19.95 million | ($0.89) | -5.60 |
| Allurion Technologies | $17.21 million | 0.51 | -$7.20 million | ($2.03) | -0.29 |
Allurion Technologies has lower revenue, but higher earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Exagen has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500.
Profitability
This table compares Exagen and Allurion Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exagen | -29.49% | -94.37% | -28.96% |
| Allurion Technologies | -199.96% | N/A | -77.13% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Exagen and Allurion Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exagen | 1 | 0 | 8 | 1 | 2.90 |
| Allurion Technologies | 1 | 1 | 1 | 0 | 2.00 |
Exagen presently has a consensus price target of $9.11, suggesting a potential upside of 82.81%. Allurion Technologies has a consensus price target of $45.00, suggesting a potential upside of 7,658.62%. Given Allurion Technologies’ higher possible upside, analysts plainly believe Allurion Technologies is more favorable than Exagen.
Summary
Exagen beats Allurion Technologies on 11 of the 15 factors compared between the two stocks.
About Exagen
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
